Background: Isocitrate dehydrogenase (IDH) 1 or IDH2 mutations or co-mutations have been associated with various tumors, including glioma. HMPL-306 (’306) is a novel, small-molecule, orally available, ...

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.

HMPL-306 will be administered orally, once daily in a 28-day continuous dosing treatment cycle. The HMPL-306 dose will be escalated in Part 1 according to the modified toxicity probability interval-2 ...